Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery

Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in various hematological malignancies and is set to lead the way for the era of adoptive T cell therapy in these type of malignancies1-9. CARs are genetically engineered surface receptors consisting of an extracellular antigen-binding domain that recognizes a specific tumor antigen, intracellular T cell signaling domains i.e. CD3zeta, and co-stimulatory molecules such as CD28 and 4-1BB10. When incorporated on autologous T cells, CARs redirect the specificity and function of T cells, that are hence able to recognize specific tumor antigens independent of human leucocyte antigen or major histocompatibility complex11.

Source: Biology of Blood and Marrow Transplantation - February 19, 2020 Category: Hematology Authors: Victoria Gutgarts, Tania Jain, Junting Zheng, Molly A. Maloy, Josel D. Ruiz, Martina Pennisi, Edgar A. Jaimes, Miguel-Angel Perales, Insara Jaffer Sathick Source Type: research